
Waypoint Bio engineers AI-designed CAR T therapies for solid tumors using spatial biology.
waypointbio.comCrawled Oct 14, 2026
Waypoint Bio harnesses high throughput and high resolution technologies to advance cell therapy, compressing years of work into a single experiment.
The company is building a team of scientists to address challenges in cell therapy, autoimmune diseases, and cancer treatment.
The company team has experience in spatial biology, computational biology, machine learning, and genomics technology development, and brings novel approaches to its mission.
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Waypoint Bio, a New York City-based startup, raises $20 million in Series A financing to test multiple cell therapies in China, including three CAR-T trials. Amplify Partners leads the financing, and investor Elliot Hershberg joins the company's board of directors.
May 2026 · Endpoints NewsNews article
Waypoint Bio appoints Patrick Kaifosh, Ph.D., as chief technology officer, adding a leader with experience in neurotechnology and artificial intelligence. Kaifosh previously led research as director of research science at Meta and co-founded CTRL-Labs, which was acquired by Meta in 2019.
Oct 2025 · Waypoint BioNews article
JLL completes a new lab lease for Waypoint Bio at 430 East 29th Street in New York. Waypoint Bio is relocating as it expands, and the article also describes its founders, spatial-biology platform, and funding.
Dec 2024 · citybizNews article
Waypoint Bio is named an up-and-comer in GEN’s Top 10 Spatial Biology Companies of 2024 list. The recognition highlights the company’s approach of combining spatial biology with pooled screening for drug discovery.
Oct 2024 · GENNews article